Grants and Contributions

This award will be given annually to the highest-ranking Early Career Researchers in the Project Grant competition that fall within the CIHR Institute of Cancer Research (CIHR-ICR) mandate:
• ICR has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.

Dr. Menten's outstanding career as a biomedical scientist led to many achievements including important co-discoveries relating to blood sugar, haemoglobin and kidney functions. In 1913, a collaboration with Leonor Michaelis on the behaviour of enzymes resulted in the Michaelis-Menten equation, a biochemical concept so fundamental that it is familiar to first-year science students.
This Maud Menten New Principal Investigator Prize was established to recognize and support the research excellence of Canadian Early-Career Investigators working within the mandate of the CIHR Institute of Genetics (CIHR-IG).
This prize is a supplemental grant to support research and must be used according to the Canadian Institutes of Health Research (CIHR) Application Canadian Institutes of Health Research (CIHR) Application Administration Guide. . The prize is not a personal award and is non-renewable.

IG Strategic Research Priorities

• Strengthening the IG Research Community
• Addressing Health & Health System Priorities:
o Computational and Systems Biology
o From Models and Mechanisms to Therapies
o Health Services, Policy & Ethical, Legal and Social Issues Research
• Fostering Innovation, Commercialization & Translation Through Partnerships

Dr. Menten's outstanding career as a biomedical scientist led to many achievements including important co-discoveries relating to blood sugar, haemoglobin and kidney functions. In 1913, a collaboration with Leonor Michaelis on the behaviour of enzymes resulted in the Michaelis-Menten equation, a biochemical concept so fundamental that it is familiar to first-year science students.
This Maud Menten New Principal Investigator Prize was established to recognize and support the research excellence of Canadian Early-Career Investigators working within the mandate of the CIHR Institute of Genetics (CIHR-IG).
This prize is a supplemental grant to support research and must be used according to the Canadian Institutes of Health Research (CIHR) Application Canadian Institutes of Health Research (CIHR) Application Administration Guide. . The prize is not a personal award and is non-renewable.

The CIHR Institute of Gender and Health (CIHR-IGH) will fund applications that are relevant to its mandate and research priorities, as described in our new Research Priority Plan, and that are aligned with at least one of the following research areas.
Research Areas:
1. Advancing intersectionality in sex and gender science (1 grant)
2. Understanding sex and gender mechanisms and processes (1 grant)
3. Sex and gender science for health equity in priority communities (2 grants)

For the purpose of this PA, sport is defined as "Activities that develop specific skills, and that are organized around competition and governed by rules" and will contribute to the National Women's Health Research Initiative (NWHRI) which is advancing a coordinated research program that addresses under-researched and high-priority areas of women's health and will ensure new evidence improves women's and gender-diverse people's care and health outcomes.

The CIHR Institute of Cancer Research (CIHR-ICR) has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.

This PA will fund Cancer research in the following priority areas:

• Cancer Prevention and/or Early Detection of Cancer
o research that prevents the onset of cancer (lowers cancer risk) and/or reduces the severity of the disease through early detection when it is at its most treatable.
• Cancer Survivorship
o research that mitigates the challenges experienced along the cancer survivorship journey and improves the health outcomes for cancer survivors of all ages after cancer treatment ends.
o specifically in the areas of:
¿ Late and long-term effects of cancer treatment
¿ Survivors’ experiences and outcomes
¿ Models of care for cancer survivorship
o This PA will not fund research focused on improving end-of-life care.

This PA supports research that creates new knowledge and/or moves it into practice in the health system, communities, workplaces, and in the daily lives of Canadians.

The CIHR Institute of Circulatory and Respiratory Health (CIHR-ICRH) has the broad mandate of supporting research on the heart, lung, brain (stroke), blood, blood vessels, critical and intensive care, and sleep.
This Priority Announcement is focused on inherited blood disorders across the lifespan.
• The proposed research should inform the prevention and treatment of end-organ damage, the development of new and/or curative therapies and/or interventions aimed at improving quality of life.
• Research focusing on more than one (1) developmental or intergenerational period over the lifespan is encouraged. Examples include, but are not limited to:
o one developmental period before and after age 18, or
o different developmental periods across generations (e.g. biological parent and fetus or offspring), or
o two (2) developmental periods in females related to puberty, child-bearing age and menopause.
• Sex and gender consideration should be integrated as appropriate.

The CIHR Antimicrobial Resistance (AMR) Research Initiative supports the development of broader, more cohesive engagement and actions, methods and tools to combat AMR and improve antimicrobial use.

In alignment with CIHR’s commitment to equity, diversity and inclusion (EDI) in the research system, the Research Initiative champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply.

The CIHR Institute of Cancer Research (CIHR-ICR) has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.
This PA will fund Breast Cancer research in the following priority areas:
• General Breast Cancer Research
o research that supports CIHR-ICR’s mandate in the area of Breast Cancer.
• Breast Cancer Prevention and/or Early Detection of Breast Cancer
o research that prevents the onset of breast cancer (lowers cancer risk) and/or reduces the severity of the disease through early detection when it is at its most treatable.
• Breast Cancer Survivorship
o research that mitigates the challenges experienced along the breast cancer survivorship journey and improves the health outcomes for breast cancer survivors of all ages after cancer treatment ends.
o specifically in the areas of:
¿ Late and long-term effects of cancer treatment
¿ Survivors’ experiences and outcomes
¿ Models of care for cancer survivorship
o This PA will not fund research focused on improving end-of-life care.
• This PA supports research that creates new knowledge and/or moves it into practice in the health system, communities, workplaces, and in the daily lives of Canadians.

The Project Grant program is expected to:
• Support a diverse portfolio of health-related research and knowledge translation proposals at any stage, from discovery to application, including commercialization;
• Promote relevant collaborations across disciplines, professions, and sectors; and
• Contribute to the creation and use of health-related knowledge.